Authors

  • Kasymov A.A., Ruziyeva N.A.

Keywords:

gastric cancer, molecular profiling, precision oncology, biomarkers, HER2, PD-L1 CPS, MSI-H dMMR, CLDN18.2, immunotherapy, targeted therapy.

References

Ajani J. A., et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology. Practice Guideline. 2025.

Lordick F., Carneiro F., Cascinu S., et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2022;33(10):1005–1020. doi: 10.1016/j.annonc.2022.07.004.

The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209. Published 23 July 2014. doi: 10.1038/nature13480.

Al-Batran S.-E., Homann N., Pauligk C., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma FLOT4: a randomised, phase 2/3 trial. The Lancet. 2019.

Janjigian Y. Y., Shitara K., Moehler M., et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma CheckMate 649: a randomised, open-label, phase 3 trial. The Lancet. 2021. doi: 10.1016/S0140-6736(21)00797-2.

Janjigian Y. Y., Kawazoe A., Yañez P., et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. 2023.

Shitara K., Bang Y.-J., Iwasa S., et al. Trastuzumab deruxtecan in previously treated HER2 -positive gastric cancer. The New England Journal of Medicine. 2020;382:2419–2430. doi: 10.1056/NEJ Moa2004413.

Shitara K., Özgüroğlu M., Bang Y.-J., et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma SPOTLIGHT: a multicentre, randomised, double-blind, phase 3 trial. 2023.